If You Invested in Lipella Pharmaceuticals Inc (LIPO)

Lipella Pharmaceuticals Inc. (LIPO) is a clinical-stage biotechnology company in the professional, scientific, and technical services sector. According to the company’s disclosures, Lipella focuses on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new therapeutic applications. The company targets diseases with significant unmet medical needs, where no approved drug therapies currently exist, and has described itself as advancing therapies for serious, often chronic conditions.

Lipella’s work centers on mucosal delivery solutions and locally delivered therapies. The company has reported multiple clinical programs built around liposomal formulations of tacrolimus delivered as oral rinses. These programs are designed to provide localized therapeutic effects while minimizing systemic exposure, an approach highlighted repeatedly in both press releases and SEC filings.

Core Programs and Clinical Focus

A key area of focus for Lipella is oral lichen planus (OLP), a chronic inflammatory condition of the oral mucosa associated with pain, erosions, ulcerations, and functional impairment. Company communications state that OLP affects an estimated 6 million Americans and that there are no FDA-approved therapies, leaving patients reliant on off-label treatments. Lipella’s pipeline includes:

• LP-10: A proprietary liposomal formulation of tacrolimus designed as an oral rinse for OLP. In a completed Phase 2a multicenter, dose-ranging study, LP-10 was administered as a 3-minute oral rinse twice daily for four weeks, followed by a two-week safety follow-up. The company reported that the study met its primary safety endpoint and achieved statistically significant improvements across all efficacy measures at the four-week timepoint. All 27 enrolled adults completed treatment, no serious adverse events were reported, systemic exposure was minimal, and treatment-related adverse events were generally mild to moderate, with dry mouth noted as the most common. Investigator and patient-reported outcomes showed reductions in ulceration, erythema, pain, and overall symptom burden, with benefits maintained through the two-week follow-up period.
• LP-310: A liposomal tacrolimus oral rinse formulation of LP-10 being evaluated for OLP in a separate Phase 2a multicenter, dose-ranging trial. In this study, LP-310 has been administered as a 10-milliliter oral rinse, with dose cohorts at 0.25 mg, 0.50 mg, and 1.0 mg of tacrolimus. Company reports describe statistically significant improvements in multiple endpoints for the 0.50 mg cohort, including Investigator Global Assessment scores, Reticulation/Erythema/Ulceration (REU) scores, Oral Lichen Planus Symptom Severity Measure (OLPSSM), pain numerical rating scales, and Global Response Assessment. LP-310 has been characterized as a non-steroidal, locally delivered therapy with undetectable or minimal systemic tacrolimus levels and no treatment-related serious adverse events.

Beyond OLP, Lipella has identified additional programs that leverage similar technology platforms. Company statements note that LP-10 has previously demonstrated safety and preliminary efficacy in a Phase 2a study for hemorrhagic cystitis, and that the company’s clinical pipeline includes LP-10 for hemorrhagic cystitis and LP-50 for bladder cancer. These programs reflect Lipella’s broader focus on mucosal disorders and urologic indications, where localized drug delivery and improved tolerability are important.

Technology and Intellectual Property

Lipella emphasizes liposomal formulations and mucosal delivery as core elements of its approach. In its public communications, the company has described its strategy as reformulating existing active agents into new delivery formats to address limitations of current topical or systemic treatments. An example is the use of liposomal tacrolimus in oral rinses designed to achieve effective local concentrations with minimal systemic absorption.

The company has also reported the issuance of U.S. Patent No. 12,326,492, titled “Systems and Methods of Detecting Interstitial Cystitis.” This patent covers a method using magnetic resonance imaging (MRI) to detect lesions or permeability defects in body cavities. Lipella has stated that this method can potentially enhance outcome assessments in its mucosal disorder programs, including LP-310 for oral lichen planus, LP-10 for hemorrhagic cystitis, and LP-50 for bladder cancer, and that the underlying MRI contrast approach may itself become a clinically relevant early detection tool.

Regulatory and Clinical Development Path

Lipella describes itself as a clinical-stage company, meaning its product candidates are in human trials but not yet approved for commercial sale. The company has communicated plans to advance LP-10 into late-stage development following positive Phase 2a results, including preparation of a Phase 2b protocol incorporating FDA feedback, scaling manufacturing capabilities to support larger clinical trials, and exploring strategic partnerships and collaborations.

For LP-310, the company has reported completion of enrollment across all three dose cohorts in its Phase 2a trial and has outlined development steps such as reporting final topline data, submitting an Investigational New Drug (IND) application for a Phase 2b trial, and exploring potential regulatory designations. Throughout its disclosures, Lipella highlights that its programs are directed at conditions with no FDA-approved therapies and significant unmet need.

Corporate and Listing Status

Lipella Pharmaceuticals Inc. is incorporated in Delaware and has identified its principal executive offices in Pittsburgh, Pennsylvania in SEC filings. The company completed its initial public offering in 2022. Its common stock has traded under the symbol LIPO.

According to a Form 8-K dated June 20, 2025, and a subsequent Form 25 filed by Nasdaq Stock Market LLC, Lipella’s common stock was delisted from The Nasdaq Capital Market. The Nasdaq Hearings Panel determined to delist the company’s common stock under Nasdaq Listing Rule 5100 due to non-compliance with Listing Rules 5635(d) and 5640 related to certain private placement transactions involving Series C voting convertible preferred stock and warrants. Trading on Nasdaq was suspended as of June 20, 2025. SEC filings state that the company’s common stock is quoted on the OTC market under the symbol “LIPO,” and that Lipella remains a reporting company under the Securities Exchange Act of 1934, continuing to file periodic reports and disclosures with the U.S. Securities and Exchange Commission.

In a stockholder letter referenced in a June 25, 2025 Form 8-K, the company’s CEO addressed the delisting, noting that Lipella remains operational, that clinical programs are advancing, and that the company intends to pursue relisting on a national exchange. The letter also referenced Lipella’s clinical pipeline and its focus on diseases with significant unmet need.

Collaborations and Operations

Lipella has disclosed a manufacturing collaboration with Cook MyoSite, Inc. to support Chemistry, Manufacturing and Control (CMC) documentation for clinical products LP-10 and LP-310. Company statements describe Cook MyoSite as a partner with experience in high-quality manufacturing and regulated clinical studies. Lipella has characterized this collaboration as important as its clinical pipeline matures toward potential commercial assets.

Across its announcements, Lipella consistently describes its business model as reformulating active agents in existing generic drugs, optimizing these reformulations for new indications, and targeting conditions with limited or no approved therapies. Its emphasis on mucosal delivery, liposomal formulations, and MRI-based diagnostic methods reflects a specialized focus within biotechnology research and development.

Frequently Asked Questions About Lipella Pharmaceuticals (LIPO)